PaulF.FewsterX-RayScatteringfromSemiconductorsandOtherMaterials3rdEditionWorldScientificPublishingCoPteLtd2015512PDF且可复制978-981-4436-92-2,978-981-4436-94-6,978-981-4436-93-...

一志愿武汉理工大学080500学硕，本科济南大学高分子材料与工程专业，初试总分346分，政治54，英语一62，数学二105，高分子化学125，四六级已过，有一部分科研经历，求调剂A区

346求调剂

20DOI:10.3929/ETHZ-A-002047499https://www.semanticscholar.org/paper/Blowing-and-drifting-snow-in-alpine-terrain%3A-A-and-Gauer/54c1509fdffeececf1e4846543371c7477e01bb8

RobertLColemanEfficacyandsafetyoftisotumabvedotininpreviouslytreatedrecurrentormetastaticcervicalcancer(innovaTV204/GOG-3023/ENGOT-cx6):amulticentre,open-label,single-arm,phase...

ProfAnaOaknin,MDAtezolizumabplusbevacizumabandchemotherapyformetastatic,persistent,orrecurrentcervicalcancer(BEATcc):arandomised,open-label,phase3trialLancet.202431-4310.1016/S...

UshaRLalchandani1,VaibhavSahaiARadiologist\'sGuidetoResponseEvaluationCriteriainSolidTumorsCurrProblDiagnRadiol.2019576-585.doi:10.1067/j.cpradiol.2018.07.016.Epub2018Aug2.

LHSchwartz1,JBogaerts,RFord,LShankarEvaluationoflymphnodeswithRECIST1.1EurJCancer.200945(2):261-7DOI:10.1016/j.ejca.2008.10.028

EricaCNakajima1,AmberSimpsonTumorSizeIsNotEverything:AdvancingRadiomicsasaPrecisionMedicineBiomarkerinOncologyDrugDevelopmentandClinicalCare....

EALiechty1,EDonovan,DPurohitReductionofneonatalmortalityaftermultipledosesofbovinesurfactantinlowbirthweightneonateswithrespiratorydistresssyndromePediatrics.199188(1):19-28

RFSoll1,REHoekstra,JJFangman,Multicentertrialofsingle-dosemodifiedbovinesurfactantextract(Survanta)forpreventionofrespiratorydistresssyndrome....

工作地点：北京大学岗位职责：熟练、独立完成常规分子生物学实验，WesternBlot(WB),实时荧光定量PCR(qPCR)等分子实验。任职要求：学历不限（本科或以上学历优先），熟悉WB及QPCR技术，最好...

AnaOakninCemiplimabinrecurrentcervicalcancer:FinalanalysisofoverallsurvivalinthephaseIIIEMPOWER-Cervical1/GOG-3016/ENGOT-cx9trialEurJCancer.20255:216:115146.10.1016/j.ejca.2024...

KrishnansuSTewariSurvivalwithCemiplimabinRecurrentCervicalCancerNEnglJMed.2022544-555DOI:10.1056/NEJMoa2112187

DavidScottMillerEvaluationofpemetrexed(Alimta,LY231514)assecondlinechemotherapyinpersistentorrecurrentcarcinomaofthecervix:...

IsabelleCadronChemotherapyforrecurrentcervicalcancerGynecolOncol.2007107(1Suppl1):S113-810.1016/j.ygyno.2007.07.004

IsabelleCadronChemotherapyforrecurrentcervicalcancerGynecolOncol.2007107(1Suppl1):S113-810.1016/S0140-6736(18)32470-X

PaulACohenCervicalcancerLancet.2019169-18210.1016/S0140-6736(18)32470-X

XiangyuGaoSafetyandantitumouractivityofcadonilimab,ananti-PD-1/CTLA-4bispecificantibody,forpatientswithadvancedsolidtumours(COMPASSION-03):amulticentre,open-label,phase1b/2...

SamEllaInvestigationofrubberfrictiononsnowfortyresTribologyInternational201359292-301https://doi.org/10.1016/j.triboint.2012.01.017ScienceDirect(Elsevier)(CellPress)

JaimeCoronelWeeklytopotecanassecond-orthird-linetreatmentinpatientswithrecurrentormetastaticcervicalcancerMedOncol.2009210-410.1007/s12032-008-9108-5

RPSymondsSCOTCERV:aphaseIItrialofdocetaxelandgemcitabineassecondlinechemotherapyincervicalcancerGynecolOncol.2011105-910.1056/NEJMra1703481

MichaelAPostowImmune-RelatedAdverseEventsAssociatedwithImmuneCheckpointBlockadeNEnglJMed.2018158-16810.1056/NEJMra1703481

GiuseppeCarusoCervicalcancer:aneweraIntJGynecolCancer.20241946-1970

GuilingLiPhaseIIstudyofenlonstobart(SG001),anovelPD-1inhibitorinpatientswithPD-L1positiverecurrent/metastaticcervicalcancerGynecolOncol.2024165-171DOI:10.1016/j.ygyno.2024.10....